About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 521248, 10 pages
http://dx.doi.org/10.1155/2010/521248
Review Article

Application of Adoptive T-Cell Therapy Using Tumor Antigen-Specific T-Cell Receptor Gene Transfer for the Treatment of Human Leukemia

1Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan
2Department of Cell Growth and Cancer Regulation, Ehime University Proteomedicine Research Center, Shitsukawa, Toon, Ehime 791-0295, Japan

Received 11 December 2009; Accepted 13 February 2010

Academic Editor: Kim Klonowski

Copyright © 2010 Toshiki Ochi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. A. Rosenberg and M. E. Dudley, “Adoptive cell therapy for the treatment of patients with metastatic melanoma,” Current Opinion in Immunology, vol. 21, no. 2, pp. 233–240, 2009. View at Publisher · View at Google Scholar · View at PubMed
  2. L. A. Johnson, R. A. Morgan, M. E. Dudley, et al., “Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen,” Blood, vol. 114, no. 3, pp. 535–546, 2009. View at Publisher · View at Google Scholar · View at PubMed
  3. R. A. Morgan, M. E. Dudley, J. R. Wunderlich, et al., “Cancer regression in patients after transfer of genetically engineered lymphocytes,” Science, vol. 314, no. 5796, pp. 126–129, 2006. View at Publisher · View at Google Scholar · View at PubMed
  4. J. D. Abad, C. Wrzensinski, W. Overwijk, et al., “T-cell receptor gene therapy of established tumors in a murine melanoma model,” Journal of Immunotherapy, vol. 31, no. 1, pp. 1–6, 2008. View at Publisher · View at Google Scholar · View at PubMed
  5. M. A. De Witte, A. Jorritsma, A. Kaiser, et al., “Requirements for effective antitumor responses of TCR transduced T cells,” Journal of Immunology, vol. 181, no. 7, pp. 5128–5136, 2008.
  6. M. H. Qazilbash, E. D. Wieder, P. F. Thall, et al., “PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia,” Blood, vol. 110, p. 90a, 2007, abstract no. 283.
  7. U. Keilholz, A. Letsch, A. Busse, et al., “A clinical and immunological phase II trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS,” Blood, vol. 113, no. 26, pp. 6541–6548, 2009.
  8. S.-A. Xue, L. Gao, D. Hart, et al., “Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells,” Blood, vol. 106, no. 9, pp. 3062–3067, 2005. View at Publisher · View at Google Scholar · View at PubMed
  9. B. Mommaas, A. G. S. van Halteren, J. Pool, et al., “Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer,” Haematologica, vol. 90, no. 10, pp. 1415–1421, 2005.
  10. M. H. M. Heemskerk, M. Hoogeboom, R. A. de Paus, et al., “Redirection of antileukemic reactivity of peripheral T lymphocytes using genetransfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region,” Blood, vol. 102, no. 10, pp. 3530–3540, 2003. View at Publisher · View at Google Scholar · View at PubMed
  11. T. Tsuji, M. Yasukawa, J. Matsuzaki, et al., “Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes,” Blood, vol. 106, no. 2, pp. 470–476, 2005. View at Publisher · View at Google Scholar · View at PubMed
  12. P. L. Weiden, N. Flournoy, and E. D. Thomas, “Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts,” New England Journal of Medicine, vol. 300, no. 19, pp. 1068–1073, 1979.
  13. P. L. Weiden, K. M. Sullivan, N. Flournoy, R. Storb, and E. D. Thomas, “Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation,” New England Journal of Medicine, vol. 304, no. 25, pp. 1529–1533, 1981.
  14. F. Michor, T. P. Hughes, Y. Iwasa, et al., “Dynamics of chronic myeloid leukaemia,” Nature, vol. 435, no. 7046, pp. 1267–1270, 2005. View at Publisher · View at Google Scholar · View at PubMed
  15. N. P. Shah, B. J. Skaggs, S. Branford, et al., “Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency,” Journal of Clinical Investigation, vol. 117, no. 9, pp. 2562–2569, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. J. J. Molldrem, P. P. Lee, C. Wang, et al., “Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia,” Nature Medicine, vol. 6, no. 9, pp. 1018–1023, 2000. View at Publisher · View at Google Scholar · View at PubMed
  17. K. Rezvani, M. Grube, J. M. Brenchley, et al., “Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation,” Blood, vol. 102, no. 8, pp. 2892–2900, 2003. View at Publisher · View at Google Scholar · View at PubMed
  18. Y. Oka, A. Tsuboi, T. Taguchi, et al., “Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 38, pp. 13885–13890, 2004. View at Publisher · View at Google Scholar · View at PubMed
  19. S. A. Rosenberg, J. C. Yang, and N. P. Restifo, “Cancer immunotherapy: moving beyond current vaccines,” Nature Medicine, vol. 10, no. 9, pp. 909–915, 2004. View at Publisher · View at Google Scholar · View at PubMed
  20. M. E. Dudley, J. R. Wunderlich, P. F. Robbins, et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,” Science, vol. 298, no. 5594, pp. 850–854, 2002. View at Publisher · View at Google Scholar · View at PubMed
  21. C. Yee, J. A. Thompson, D. Byrd, et al., “Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16168–16173, 2002. View at Publisher · View at Google Scholar · View at PubMed
  22. N. N. Hunder, H. Wallen, J. Cao, et al., “Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1,” New England Journal of Medicine, vol. 358, no. 25, pp. 2698–2703, 2008. View at Publisher · View at Google Scholar · View at PubMed
  23. E. Marijt, A. Wafelman, M. van der Hoorn, et al., “Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation,” Haematologica, vol. 92, no. 1, pp. 72–80, 2007. View at Publisher · View at Google Scholar
  24. H.-J. Kolb, “Graft-versus-leukemia effects of transplantation and donor lymphocytes,” Blood, vol. 112, no. 12, pp. 4371–4383, 2008. View at Publisher · View at Google Scholar · View at PubMed
  25. J. H. F. Falkenburg, A. R. Wafelman, P. Joosten, et al., “Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes,” Blood, vol. 94, no. 4, pp. 1201–1208, 1999.
  26. S.-A. Xue, L. Gao, S. Thomas, et al., “Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice,” Haematologica, vol. 95, no. 1, pp. 126–134, 2010. View at Publisher · View at Google Scholar · View at PubMed
  27. S. Thomas, S.-A. Xue, M. Cesco-Gaspere, et al., “Targeting the wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells,” Journal of Immunology, vol. 179, no. 9, pp. 5803–5810, 2007.
  28. S. Okamoto, J. Mineno, H. Ikeda, et al., “Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR,” Cancer Research, vol. 69, no. 23, pp. 9003–9011, 2009. View at Publisher · View at Google Scholar · View at PubMed
  29. M. H. M. Heemskerk, M. Hoogeboom, R. Hagedoorn, M. G. D. Kester, R. Willemze, and J. H. F. Falkenburg, “Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer,” Journal of Experimental Medicine, vol. 199, no. 7, pp. 885–894, 2004. View at Publisher · View at Google Scholar · View at PubMed
  30. Z. Dembic, W. Haas, and S. Weiss, “Transfer of specificity by murine α and β T-cell receptor genes,” Nature, vol. 320, no. 6059, pp. 232–238, 1986.
  31. T. M. Clay, M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura, “Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity,” Journal of Immunology, vol. 163, no. 1, pp. 507–513, 1999.
  32. R. A. Willemsen, M. E. M. Weijtens, C. Ronteltap, et al., “Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR,” Gene Therapy, vol. 7, no. 16, pp. 1369–1377, 2000.
  33. A. Hiasa, M. Hirayama, H. Nishikawa, et al., “Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) αβ genes transduced to CD8+ T cells,” Gene Therapy, vol. 15, no. 9, pp. 695–699, 2008. View at Publisher · View at Google Scholar · View at PubMed
  34. R. A. Morgan, M. E. Dudley, Y. Y. L. Yu, et al., “High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens,” Journal of Immunology, vol. 171, no. 6, pp. 3287–3295, 2003.
  35. Y. Zhao, Z. Zheng, P. F. Robbins, H. T. Khong, S. A. Rosenberg, and R. A. Morgan, “Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines,” Journal of Immunology, vol. 174, no. 7, pp. 4415–4423, 2005.
  36. Y. Date, A. Kimura, H. Kato, and T. Sasazuki, “DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese,” Tissue Antigens, vol. 47, no. 2, pp. 93–101, 1996.
  37. P. Krausa, M. Brywka III, U. Savage, et al., “Genetic polymorphism within HLA-A02: significant allelic variation revealed in different populations,” Tissue Antigens, vol. 45, no. 4, pp. 223–231, 1995.
  38. H. Ohminami, M. Yasukawa, and S. Fujita, “HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T- lymphocyte clone specific for WT1 peptide,” Blood, vol. 95, no. 1, pp. 286–293, 2000.
  39. M. Yasukawa, H. Fujiwara, T. Ochi, et al., “Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome,” American Journal of Hematology, vol. 84, no. 5, pp. 314–315, 2009. View at Publisher · View at Google Scholar · View at PubMed
  40. L. Duval, H. Schmidt, K. Kaltoft, et al., “Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma,” Clinical Cancer Research, vol. 12, no. 4, pp. 1229–1236, 2006. View at Publisher · View at Google Scholar · View at PubMed
  41. M. E. Call and K. W. Wucherpfennig, “The T cell receptor: critical role of the membrane environment in receptor assembly and function,” Annual Review of Immunology, vol. 23, pp. 101–125, 2005. View at Publisher · View at Google Scholar · View at PubMed
  42. M. H. M. Heemskerk, R. S. Hagedoorn, M. A. W. G. van der Hoorn, et al., “Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex,” Blood, vol. 109, no. 1, pp. 235–243, 2007. View at Publisher · View at Google Scholar · View at PubMed
  43. C. J. Cohen, Y. Zhao, Z. Zheng, S. A. Rosenberg, and R. A. Morgan, “Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability,” Cancer Research, vol. 66, no. 17, pp. 8878–8886, 2006. View at Publisher · View at Google Scholar · View at PubMed
  44. C. J. Cohen, Y. F. Li, M. El-Gamil, P. F. Robbins, S. A. Rosenberg, and R. A. Morgan, “Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond,” Cancer Research, vol. 67, no. 8, pp. 3898–3903, 2007. View at Publisher · View at Google Scholar · View at PubMed
  45. J. Kuball, M. L. Dossett, M. Wolfl, et al., “Facilitating matched pairing and expression of TCR chains introduced into human T cells,” Blood, vol. 109, no. 6, pp. 2331–2338, 2007. View at Publisher · View at Google Scholar · View at PubMed
  46. Z. Sebestyen, E. Schooten, T. Sals, et al., “Human TCR that incorporate CD3ζ induce highly preferred pairing between TCRα and β chains following gene transfer,” Journal of Immunology, vol. 180, no. 11, pp. 7736–7746, 2008.
  47. K. B. J. Scholten, D. Kramer, E. W. M. Kueter, et al., “Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells,” Clinical Immunology, vol. 119, no. 2, pp. 135–145, 2006. View at Publisher · View at Google Scholar · View at PubMed
  48. L. T. van der Veken, R. S. Hagedoorn, M. M. van Loenen, R. Willemze, J. H. F. Falkenburg, and M. H. M. Heemskerk, “αβ T-cell receptor engineered γδ T cells mediate effective antileukemic reactivity,” Cancer Research, vol. 66, no. 6, pp. 3331–3337, 2006. View at Publisher · View at Google Scholar · View at PubMed
  49. A. Hiasa, H. Nishikawa, M. Hirayama, et al., “Rapid αβ TCR-mediated responses in γδ T cells transduced with cancer-specific TCR genes,” Gene Therapy, vol. 16, no. 5, pp. 620–628, 2009. View at Publisher · View at Google Scholar · View at PubMed
  50. W. R. Burns, Z. Zheng, S. A. Rosenberg, and R. A. Morgan, “Lack of specific γ-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation,” Blood, vol. 114, no. 14, pp. 2888–2899, 2009. View at Publisher · View at Google Scholar · View at PubMed
  51. M. A. Pule, B. Savoldo, G. D. Myers, et al., “Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma,” Nature Medicine, vol. 14, no. 11, pp. 1264–1270, 2008. View at Publisher · View at Google Scholar · View at PubMed
  52. C. Berger, M. C. Jensen, P. M. Lansdorp, M. Gough, C. Elliott, and S. R. Riddell, “Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates,” Journal of Clinical Investigation, vol. 118, no. 1, pp. 294–305, 2008. View at Publisher · View at Google Scholar · View at PubMed
  53. C. S. Hinrichs, Z. A. Borman, L. Cassard, et al., “Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 41, pp. 17469–17474, 2009. View at Publisher · View at Google Scholar · View at PubMed
  54. A. U. van Lent, M. Nagasawa, M. M. van Loenen, et al., “Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors,” Journal of Immunology, vol. 179, no. 8, pp. 4959–4968, 2007.
  55. Y. Zhao, M. R. Parkhurst, Z. Zheng, et al., “Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via notch signaling,” Cancer Research, vol. 67, no. 6, pp. 2425–2429, 2007. View at Publisher · View at Google Scholar · View at PubMed
  56. C. Bonini, G. Ferrari, S. Verzeletti, et al., “HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia,” Science, vol. 276, no. 5319, pp. 1719–1724, 1997. View at Publisher · View at Google Scholar
  57. F. Ciceri, C. Bonini, S. Marktel, et al., “Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation,” Blood, vol. 109, no. 11, pp. 4698–4707, 2007. View at Publisher · View at Google Scholar · View at PubMed
  58. F. Ciceri, C. Bonini, M. T. L. Stanghellini, et al., “Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study,” The Lancet Oncology, vol. 10, no. 5, pp. 489–500, 2009. View at Publisher · View at Google Scholar
  59. A. Recchia, C. Bonini, Z. Magnani, et al., “Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1457–1462, 2006. View at Publisher · View at Google Scholar · View at PubMed
  60. N. Cartier, S. Hacein-Bey-Abina, C. C. Bartholomae, et al., “Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy,” Science, vol. 326, no. 5954, pp. 818–823, 2009. View at Publisher · View at Google Scholar · View at PubMed
  61. A. Aiuti, F. Cattaneo, S. Galimberti, et al., “Gene therapy for immunodeficiency due to adenosine deaminase deficiency,” New England Journal of Medicine, vol. 360, no. 5, pp. 447–458, 2009. View at Publisher · View at Google Scholar · View at PubMed
  62. A. Krishnan, J. A. Zaia, J. Rossi, et al., “First in human engraftment of anti-HIV lentiviral vector gene modified CD34+ peripheral blood progenitor cells in the treatment of AIDS related lymphoma (ARL),” Blood, vol. 112, p. 818a, 2008, abstract no. 2348.
  63. M. L. Dossett, R. M. Teague, T. M. Schmitt, et al., “Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR,” Molecular Therapy, vol. 17, no. 4, pp. 742–749, 2009. View at Publisher · View at Google Scholar · View at PubMed
  64. T. Ochi, H. Fujiwara, and M. Yasukawa, “Aurora-A kinase: a novel target both for cellular immunotherapy and molecular target therapy against human leukemia,” Expert Opinion on Therapeutic Targets, vol. 13, no. 12, pp. 1399–1410, 2009.
  65. T. Ochi, H. Fujiwara, K. Suemori, et al., “Aurora-A kinase: a novel target of cellular immunotherapy for leukemia,” Blood, vol. 113, no. 1, pp. 66–74, 2009. View at Publisher · View at Google Scholar · View at PubMed
  66. K. Nagai, H. Fujiwara, T. Ochi, et al., “Development of a novel anti-leukemia gene immunotherapy using Aurora-A kinase-specific T-cell receptor gene transfer,” Blood, vol. 114, p. 158a, 2009, abstract no. 375.
  67. J. Arai, M. Yasukawa, H. Ohminami, M. Kakimoto, A. Hasegawa, and S. Fujita, “Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes,” Blood, vol. 97, no. 9, pp. 2903–2907, 2001. View at Publisher · View at Google Scholar